GDC-0941 activates integrin linked kinase (ILK) expression to cause resistance to GDC-0941 in breast cancer by the tumor necrosis factor (TNF)-α signaling pathway

Haifeng Chen, Ming‐Ming Cheng, Pengcheng Gao, Xianzhong Zhang, Ganggang Li, Liting Wang, Long Qin, Hongrui LiBioengineered 2022 · DOI

TL;DR

This study investigates why some breast cancer cells resist the PI3K inhibitor GDC-0941. Researchers found that GDC-0941 actually increases the expression of Integrin-linked kinase (ILK) via the TNF-α pathway, and this elevated ILK leads to resistance by affecting AKT signaling. Combining GDC-0941 with an ILK inhibitor (OSU-T315) or blocking TNF-α restored sensitivity and inhibited tumor growth.

What Problem Does This Paper Address?

Breast cancer remains a significant health challenge, and while targeted therapies like GDC-0941 (a PI3K inhibitor) show promise, a major hurdle is the development of drug resistance. GDC-0941 works by inhibiting the PI3K/AKT/mTOR pathway, crucial for cell growth and survival. However, some breast cancer cell lines are not sensitive to this drug, and the underlying mechanisms for this resistance are not fully understood. This paper aims to elucidate how GDC-0941 itself can paradoxically lead to resistance in certain breast cancer contexts, focusing on the role of Integrin-linked kinase (ILK) and the tumor necrosis factor (TNF)-α signaling pathway.

Methods

The researchers employed a multi-pronged approach:

  • In vitro cell culture: Several breast cancer cell lines (BT-474, MCF7, Hs-578-T, MDA-MB-231, MDA-MB-453, and MDA-MB-468) were used. These cells were treated with GDC-0941, an ILK inhibitor (OSU-T315), or a TNF-α antibody.
  • Genetic manipulation: Cells were transfected with ILK (to overexpress it) or shILK (to knock it down) to study ILK's specific role.
  • Cell viability assays: CCK-8 assays were used to determine the half-maximal inhibitory concentration (IC50) of GDC-0941, measuring cell survival rates.
  • Protein and mRNA analysis: Western blotting was used to detect protein levels (p-AKT, AKT, PDK1, ILK, S6, p70S6K), while quantitative real-time PCR (qPCR) was used to measure mRNA expression of ILK, PDK1, and TNF-α.
  • ELISA: Enzyme-linked immunosorbent assays were used to quantify TNF-α levels in cell culture supernatants.
  • In vivo mouse model: A xenograft mouse model of breast cancer was established by injecting HCC1937 cells into nude mice. These mice were then treated with GDC-0941, OSU-T315, or a combination, and tumor size, volume, and weight were monitored.

Datasets

Not explicitly discussed as distinct datasets. The study utilized established breast cancer cell lines and a standard mouse model for in vivo experiments.

Key Insights and Ideas

  • GDC-0941's paradoxical effect: The most striking finding is that GDC-0941, while intended to inhibit cancer growth, actually promotes the expression of ILK. This suggests a negative feedback loop or a complex interplay where the drug's action triggers a resistance mechanism.
  • TNF-α as a mediator: The study identifies TNF-α as the crucial link between GDC-0941 and ILK upregulation. GDC-0941 increases TNF-α, which in turn boosts ILK expression. This highlights the importance of inflammatory signaling in drug resistance.
  • ILK's central role in resistance: Elevated ILK levels directly correlate with reduced sensitivity to GDC-0941. Conversely, reducing ILK expression (via shILK) makes cells more sensitive to the drug. This firmly establishes ILK as a key player in GDC-0941 resistance.
  • AKT pathway modulation: ILK's effect on GDC-0941 sensitivity is mediated through its regulation of AKT phosphorylation. Overexpressing ILK leads to increased AKT phosphorylation, which GDC-0941 can partially counteract. Knocking down ILK reduces AKT phosphorylation, and GDC-0941 further enhances this reduction.
  • Synergistic therapeutic potential: Combining GDC-0941 with an ILK inhibitor (OSU-T315) or blocking TNF-α significantly enhances the drug's efficacy, leading to reduced cell survival, lower IC50 values, and inhibited tumor growth in vivo.

Key Results

  • GDC-0941 decreased cell survival and downregulated p-AKT, p-S6, and p-p70S6K in most tested cell lines.
  • However, GDC-0941 promoted ILK expression while having little effect on PDK1.
  • ILK overexpression increased resistance to GDC-0941, while ILK knockdown increased sensitivity.
  • The combination of OSU-T315 (ILK inhibitor) and GDC-0941 significantly reduced p-AKT, p-S6, and p-p70S6K levels, tumor volume, and tumor weight in mouse models.
  • GDC-0941 increased TNF-α levels, which in turn upregulated ILK expression. Blocking TNF-α with an antibody reduced ILK expression and increased GDC-0941 sensitivity.

Limitations and Future Work

  • Cell line variability: The study acknowledges that different breast cancer cell lines exhibit varying sensitivities to GDC-0941, indicating that resistance mechanisms might not be uniform across all subtypes.
  • Mechanism complexity: While TNF-α and ILK are identified as key players, the complete signaling cascade and potential compensatory mechanisms are likely more complex and warrant further investigation.
  • Future Directions: The authors suggest that combining GDC-0941 with ILK inhibitors or TNF-α modulators holds significant therapeutic promise for breast cancer treatment. Further research could explore other drugs and factors that can synergize with GDC-0941 to overcome resistance. The development of novel therapeutic dosing regimens based on these combinations is also proposed.

Summary updated

Abstract

Breast cancer is characterized by high morbidity and mortality. GDC-0941 is a PI3K inhibitor with oncogenic effects in breast cancer. However, certain breast cancer cells are insensitive to GDC-0941. Hence, the mechanism of GDC-0941 in breast cancer resistance was investigated in this study. Breast cancer cell lines BT-474, MCF7, Hs-578-T, MDA-MB-231, MDA-MB-453, and MDA-MB-468 were cultured in different medium and then treated with 100 or 500 nM GDC-0941, 100 nM OSU-T315, or TNF-α antibody. Moreover, ILK and shILK were transfected into cells. The half maximal inhibitory concentrations (IC50) for GDC-0941 were detected using CCK-8 assay. The levels of ILK, AKT, PDK1, S6, and p70S6K expression were detected using western blotting and qPCR. In addition, the mouse model of breast cancer was constructed to measure the tumor size, volume, and weight. The results showed that GDC-0941 decreased cell survival rate, downregulated the phosphorylation of AKT, S6, and p70S6K, and promoted the expression of ILK, while it had little effect on PDK1 expression. GDC-0941 inhibited the increases in p-AKT, p-S6, and p-p70S6K caused by ILK overexpression and promoted ILK knockdown-induced reduction of p-AKT, p-S6, and p-p70S6K. In addition, the combination of OSU-T315 and GDC-0941 decreased p-AKT, p-S6, and p-p70S6K level, tumor volume, and tumor weight. GDC-0941 promoted ILK expression by upregulating TNF-α level. Taken together, GDC-0941 increased ILK level by upregulating TNF-α, thus affecting AKT expression and the sensitivity of breast cancer cells to GDC-0941.
BibTeX
@inproceedings{chen2022gdc,
  author = {Haifeng Chen and Ming‐Ming Cheng and Pengcheng Gao and Xianzhong Zhang and Ganggang Li and Liting Wang and Long Qin and Hongrui Li},
  title = {{GDC-0941 activates integrin linked kinase (ILK) expression to cause resistance to GDC-0941 in breast cancer by the tumor necrosis factor (TNF)-α signaling pathway}},
  booktitle = {Bioengineered},
  year = {2022},
  doi = {10.1080/21655979.2022.2066758},
}
Figure